NCT00091182View on ClinicalTrials.gov

Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

February 28, 2006

Conditions
Childhood Central Nervous System Germ Cell TumorChildhood Extragonadal Germ Cell TumorChildhood HepatoblastomaChildhood Hepatocellular CarcinomaChildhood High-grade Cerebral AstrocytomaChildhood Low-grade Cerebral AstrocytomaChildhood Malignant Ovarian Germ Cell TumorChildhood Malignant Testicular Germ Cell TumorChildhood TeratomaRecurrent Adrenocortical CarcinomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood Liver CancerRecurrent Childhood Malignant Germ Cell TumorRecurrent Childhood RhabdomyosarcomaRecurrent Childhood Soft Tissue SarcomaRecurrent Childhood Visual Pathway and Hypothalamic GliomaRecurrent Colon CancerRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorRecurrent Nasopharyngeal CancerRecurrent NeuroblastomaRecurrent OsteosarcomaRecurrent Rectal CancerRecurrent Renal Cell Cancer
Interventions
DRUG

oxaliplatin

Given IV

Trial Locations (1)

91006-3776

Children's Oncology Group, Arcadia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00091182 - Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment | Biotech Hunter | Biotech Hunter